Namenda and Progressive multifocal leukoencephalopathy - a phase IV clinical study of FDA data

Summary:

Progressive multifocal leukoencephalopathy is reported as a side effect among people who take Namenda (memantine hydrochloride), especially for people who are female, 40-49 old, also take Tysabri, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Progressive multifocal leukoencephalopathy when taking Namenda. It is created by eHealthMe based on reports of 13,521 people who have side effects when taking Namenda from the FDA, and is updated regularly.

What is Namenda?

Namenda has active ingredients of memantine hydrochloride. It is often used in dementia. eHealthMe is studying from 14,283 Namenda users. Check the latest studies of Namenda.

What is Progressive multifocal leukoencephalopathy?

Progressive multifocal leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells) is found to be associated with 591 drugs and 921 conditions by eHealthMe. Check the latest studies of Progressive multifocal leukoencephalopathy.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Jul, 30, 2026

13,521 people reported to have side effects when taking Namenda.
Among them, 11 people (0.08%) have Progressive multifocal leukoencephalopathy.

Could Namenda cause Progressive multifocal leukoencephalopathy?

Among these 11 people:

What is the gender of people who have Progressive multifocal leukoencephalopathy when taking Namenda? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Progressive multifocal leukoencephalopathy when taking Namenda? *

What are other drugs people take besides Namenda? *

What are other side effects people have besides Progressive multifocal leukoencephalopathy? *

Urinary Tract Infection: 3 people, 27.27%
Fall: 2 people, 18.18%
Nasopharyngitis (inflammation of the nasopharynx): 2 people, 18.18%
Stress And Anxiety: 2 people, 18.18%
Weight Decreased: 1 person, 9.09%
Hypertonia (abnormal increase in muscle tension and a reduced ability of a muscle to stretch): 1 person, 9.09%
General Physical Health Deterioration (weak health status): 1 person, 9.09%
Gait Disturbance: 1 person, 9.09%
Family Stress: 1 person, 9.09%
Depression: 1 person, 9.09%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 7 people, 63.64%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 5 people, 45.45%
Pain: 1 person, 9.09%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 1 person, 9.09%
Multiple Allergies (allergy to multiple agents): 1 person, 9.09%
Itching: 1 person, 9.09%
General Symptom: 1 person, 9.09%
Constipation: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Namenda and have Progressive multifocal leukoencephalopathy?

- Check whether Progressive multifocal leukoencephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Namenda:

Namenda (14,283 reports)

Progressive multifocal leukoencephalopathy treatments and more:

Progressive multifocal leukoencephalopathy (13,731 reports)

How severe was Progressive multifocal leukoencephalopathy and when was it recovered:

Progressive multifocal leukoencephalopathy in Namenda

Expand to all the drugs that have ingredients of memantine hydrochloride:

Progressive multifocal leukoencephalopathy and drugs with ingredients of memantine hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Namenda:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (591 drugs)

Browse all the conditions that are associated with Progressive multifocal leukoencephalopathy:

Progressive multifocal leukoencephalopathy (921 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on memantine hydrochloride (the active ingredients of Namenda) and Namenda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.